Top in ID: Experimental malaria vaccine; oral antibiotics for bone and joint infections
Click Here to Manage Email Alerts
A proof-of-concept trial revealed that GA2, a second-generation vaccine candidate that uses genetically attenuated malaria parasites, prevented 89% of participants who received it from being infected with malaria.
“The aim for the genetically attenuated vaccine is to achieve much higher efficacy than the currently available vaccines,” Meta Roestenberg, MD, professor of vaccinology and clinical head of the Controlled Human Infections Center at the Leiden University Center for Infectious Diseases in the Netherlands, told Healio. “However, they are also in a much earlier development stage and far from [regulatory approval].”
It was the top story in infectious disease last week.
In another top story, researchers found that institutional guidelines for individuals with bone and joint infections to be treated with oral antibiotics led to more patients being discharged exclusively on antibiotics, shorter hospital stays and similar rates of treatment failure.
Read these and more top stories in infectious disease below:
Vaccine using live-attenuated malaria parasites shows promise
An experimental vaccine against malaria that uses live-attenuated Plasmodium falciparum malaria parasites showed promise in a small human challenge trial, researchers reported in The New England Journal of Medicine. Read more.
Oral antibiotics for bone, joint infections decrease length of hospital stay
Treating individuals with bone and joint infections with oral antibiotics led to more patients being discharged exclusively on oral antibiotics and shorter hospital stays without increasing rates of treatment failure, according to study results. Read more.
Anal high-risk HPV common among transgender women
Anal high-risk HPV and abnormal cytology were common among transgender women regardless of their age, HIV status and/or hormone use, researchers determined. Read more.
Pfizer’s RSV vaccine generates strong response in younger, immunocompromised adults
Data from the MONeT study demonstrated that Pfizer’s respiratory syncytial virus vaccine appeared safe and elicited a strong response in younger adult patients at increased risk for disease. Read more.
Does the world still need an HIV vaccine? Experts say yes
Fifteen years ago, an HIV vaccine trial conducted in Thailand and sponsored by the U.S. Army found something no other HIV vaccine trial ever had: a regimen that seemed to work. In the years since, every other late-stage HIV vaccine trial has met the same fate — ending without success. Read more.